What happened
On 12 November AMD confirmed that it will deepen its collaboration with PsiQuantum, a company developing fault‑tolerant photonic quantum computers. The expanded agreement adds AMD’s Instinct GPUs, EPYC CPUs and ROCm software stack to the existing use of AMD Versal FPGAs, and includes an equity investment from AMD, though the amount was not disclosed.
Details of the collaboration
The two firms will jointly design the hardware and software layers needed to run large‑scale quantum machines. By combining AMD’s high‑performance and AI‑focused components with PsiQuantum’s silicon‑photonic platform, they aim to create what they describe as the world’s most powerful hybrid computing fabric.
- Hardware integration: Existing work on Versal FPGAs will be complemented by AMD Instinct graphics processors and EPYC server processors.
- Software stack: The partnership will leverage AMD’s ROCm open‑source software to enable hybrid quantum‑classical workloads.
- Hybrid applications: The companies plan to develop software that blends quantum, high‑performance computing (HPC) and artificial‑intelligence (AI) techniques.
Both parties also intend to explore a joint presence at the Illinois Quantum and Microelectronics Park (IQMP) in Chicago, where PsiQuantum is the anchor tenant.
Initial focus: drug discovery
The first target application is computational chemistry for drug discovery. PsiQuantum already runs its proprietary chemistry methods on AMD GPUs, reporting breakthrough simulations of covalent inhibitors—molecules relevant to oncology research. According to a PsiQuantum press release, the collaboration has tuned a machine‑learning decoder called PRISM to run quickly on programmable chips, providing real‑time error correction for large photonic quantum systems.
Alignment with U.S. Department of Energy priorities
The partnership cites the DOE’s Quantum Genesis Priority Applications, a set of eight scientific problems that define the goals for fault‑tolerant quantum computers. These applications span chemistry, materials, sub‑atomic physics and applied mathematics. Both companies note that their focus on drug‑discovery chemistry fits within the “biology‑modeling” emerging area identified by the DOE.
Background and context
PsiQuantum selected AMD’s Versal FPGAs early in its development to build a programmable foundation for its photonic qubits. The new agreement expands that foundation to include AMD’s broader compute portfolio. In October, the Pentagon offered PsiQuantum a conditional $150 million loan, underscoring government interest in the technology. AMD, meanwhile, reported a record financial quarter and recently announced a $1 billion investment in Meta, highlighting its aggressive capital‑deployment strategy.
What it means for the industry
The expanded partnership signals a convergence of classical high‑performance hardware and emerging quantum technologies. By co‑designing the infrastructure that will run utility‑scale quantum computers, AMD positions itself as a key supplier of the classical components that will support future fault‑tolerant quantum systems. The focus on hybrid software suggests that early quantum advantage will likely emerge from tightly coupled quantum‑classical workflows, especially in domains such as drug discovery where large‑scale simulation is already a strength of GPU‑based HPC.
Both companies plan to reveal more details at the SC26 supercomputing conference in Chicago (15‑20 November), indicating that the partnership will continue to be a focal point of industry discussions around quantum‑HPC integration.
